Objectives: To characterize a novel CTX-M chimera, CTX-M-137, from Escherichia coli clinical isolates in China.
4 Different from the chimeras above, we report here a novel CTX-M chimera, CTX-M-137, with a CTX-M-14-like N-terminus and a CTX-M-15-like C-terminus, which hydrolyses both cefotaxime and ceftazidime. Access publication 28 April 2014 from urine, 32 from saliva, 7 from various secretions and 56 from sputum. Colonies consistent with E. coli were identified on MacConkey agar (Oxoid, Basingstoke, UK) plates and confirmed using API 20E system (bioMérieux, France). Susceptibility testing to b-lactams, fluoroquinolones, aminoglycosides and co-trimoxazole was carried out on the Vitek2 system (bioMérieux, France). The MICs were tested with the standard agar dilution method interpreted according to Clinical and Laboratory Standards Institute (CSLI) guidelines. 5 All isolates were screened for ESBL phenotype using CLSI disc confirmatory tests. 5 
Materials and methods

Bacterial strains and susceptibility testing
Molecular detection of resistance genes
Various genes known to confer an ESBL phenotype were screened for by PCR (Table S1 , available as Supplementary data at JAC Online). Sequencing was performed on both strands using an ABI 13700 instrument (Applied Biosystems, Foster City, CA, USA) for all PCR products except for bla TEM , which was sequenced only when other ESBL genes could not be identified by PCR.
Multilocus sequence typing (MLST)
MLST was performed for CTX-M-137-producing E. coli YM11, as previously described. 6 Cloning of bla CTX-M-137 bla CTX-M-137 was amplified by PCR using primers CTX-M-14-F with an XbaI site and CTX-M-15-R with a BamHI site. The genomic DNA of CTX-M-137-producing E. coli YM11 was extracted and digested with EcoRI. Both the PCR product and genomic DNA were then ligated to cloning vector pBC-SK (-), which had been cut by the appropriate restriction endonuclease. The ligation products were transferred to E. coli DH10B by electroporation and cultured on lysogeny broth (LB) agar supplemented with ampicillin (100 mg/L) and chloramphenicol (30 mg/L). Sequencing was performed for both PCR-generated and genomic DNA clones to confirm their identity as bla CTX-M-137 and its genetic environment.
Purification of CTX-M-137
Purification of CTX-M-137 was carried out, as previously described, 7 with modifications that the supernatant of bacterium was loaded onto a HiTrap SP HP column (GE Healthcare, Piscataway, NJ, USA) without gel filtration chromatography, and the protein was concentrated and desalinated by ultrafiltration (Millipore, MA, USA).
Kinetic measurements
The kinetic parameters (k cat and K m ) of the purified CTX-M-137 protein were determined in 50 mM phosphate buffer (pH 7.0). The 50% inhibitory concentration (IC 50 ) was determined as the clavulanic acid concentration that reduced the hydrolysis rate of 100 mM ampicillin by 50% under conditions in which the enzyme was preincubated with various concentrations of inhibitor for 5 min before addition of the substrate.
Plasmid conjugation and plasmid analysis E. coli J53 was used as the recipient for the conjugation experiment of CTX-M-137-producing E. coli YM11. The transconjugants were selected on LB agar containing ampicillin (100 mg/L) and sodium azide (100 mg/L). Plasmid analysis was carried out by PCR-based replicon typing (PBRT), 8 DNA linearization with S1 nuclease followed by PFGE and Southern hybridization using a bla CTX-M gene probe, as previously described. 9 Nucleotide sequence accession number
The nucleotide sequence reported in this study has been submitted to the GenBank database under accession number KF790923 for the bla CTX-M-137 gene.
Results
Antibiotic susceptibility testing
The susceptibilities of the cephalosporin-resistant E. coli isolates are shown in Table S2 (available as Supplementary data at JAC Online). The rates of resistance to third-and fourth-generation cephalosporins ranged between 90.7% and 98.4%. Imipenem was the most active b-lactam, with a susceptibility rate of 99.2%. The resistance rates for different b-lactams and b-lactamase inhibitors varied widely. Isolates co-resistant to third-generation cephalosporins, fluoroquinolones and aminoglycosides (multidrug resistant) made up 38.9% (96/247) of the total.
ESBL phenotype and resistance genes
Out of 247 cephalosporin-resistant E. coli isolates, 209 (84.6%) showed an ESBL phenotype, among which ESBL genes were identified for all except three isolates (Table S3, CTX-M-137-producing clinical isolate and chimeric structure of CTX-M-137 E. coli YM11, identified from the blood sample of a 60-year-old man with lung cancer who had been hospitalized with symptoms of urinary tract infection, was resistant to all the tested b-lactams except imipenem and to non-b-lactams (gentamicin, tobramycin, ciprofloxacin, levofloxacin and co-trimoxazole) and had an ESBL phenotype (Table S4 , available as Supplementary data at JAC Online).
E. coli YM11 was negative with bla CTX-M group-specific primers but positive with bla CTX-M consensus primers with a 544 bp product by PCR. Sequencing indicated that its 5 ′ terminus was identical to the bla CTX-M-14 gene and its 3 ′ terminus to the bla CTX-M-15 gene. Using the combination of a bla CTX-M-9 forward primer and a bla CTX-M-1 reverse primer to amplify the bla CTX-M gene, we obtained an 876 bp fragment with a GC content of 58.3%, in which nucleotides 1 -572 were 100% identical to those in bla CTX-M-14 (GenBank accession number AF252622) and bla CTX-M-24 , -27 , -38 , -98 , -102 , -104 , 
Resistance phenotype produced by CTX-M-137
The MICs of various b-lactams for a transconjugant with the natural CTX-M-137-encoding plasmid and a transformant with the bla CTX-M-137 gene cloned in the vector are listed in Table S4 . Both the transconjugant and the transformant conferred resistance to cefotaxime as well as ceftazidime, which was fully reversed by clavulanic acid. CTX-M-137 also conferred resistance to aztreonam, but not to cefoxitin and cefepime, although the latter had a 128-to 256-fold increase in MICs.
Kinetic properties of CTX-M-137
The kinetic parameters of CTX-M-137 are shown in Table 1 . CTX-M-137 showed hydrolysis for ampicillin, cefalotin, cefotaxime and ceftazidime. However, no hydrolysis was observed with aztreonam and cefoxitin under the experimental conditions. The IC 50 of clavulanic acid measured with ampicillin as substrate was 0.067 mM.
Plasmid DNA analysis and genetic environment of bla CTX-M-137 S1-PFGE and Southern blotting indicated that bla CTX-M-137 was on an 83 kb plasmid (data not shown). PBRT showed that the plasmid was IncI1. By cloning the genomic DNA, we obtained an 7 kb fragment consisting of an 4.5 kb fragment including bla CTX-M-137 and its surrounding sequences and another 2.5 kb fragment, which was part of IncI1 plasmid backbone. The flanking region of bla CTX-M-137 is shown in Figure 1 . ISEcp1 located upstream of bla CTX-M-137 was disrupted by IS10, which was flanked by 9 bp direct repeats (DRs; usually found at both ends of a transposon) (AATTGAGTG), indicating that this insertion was caused by transposition. A 42 bp spacer between the right inverted repeat (IRR) of the disturbed ISEcp1 and bla CTX-M-137 was identical to that of ISEcp1 (disturbed by IS10 or not)-bla CTX-M-14-like . 10 A 345 bp 5 ′ -truncated orf477 was located 47 bp downstream of the bla CTX-M-137 termination codon. An 18 bp putative IRR of ISEcp1, which was identical to the one used by ISEcp1 in the common 2971 bp ISEcp1-bla CTX-M-15 -Dorf477 transposition unit (AB701567), was found at the 5 ′ end of Dorf477. Interestingly, a 5 bp DR (TACTT) was adjacent to the left inverted repeat (IRL) of ISEcp1 and the assumed IRR of orf477, indicating a complete transposition unit with the interrupted ISEcp1-bla CTX-M-137 -Dorf477 inserted into yagA.
Discussion
In recent years, CTX-M-type ESBLs have become the predominant ESBL in E. coli. The prevalence of CTX-M-14 in our study was similar to that in previous reports. 11 Among the CTX-M-1 group ESBLs, CTX-M-3 and CTX-M-15 were reported as predominant in nationwide investigations in 2006 and 2010 in China, respectively.
11,12
Here we found CTX-M-79 to be predominant within the CTX-M-1 group ESBLs, in contrast with previous reports describing its sporadic existence. 13 CTX-M-79 has two amino acid substitutions (A77V and D288N) compared with CTX-M-15. In our study, most of the CTX-M-79-producing isolates were not clonally related by PFGE (data not shown), suggesting a plasmid-mediated spread of this gene in our region.
Here we identified CTX-M-137 on an IncI1 plasmid in E. coli YM11 typed as ST354. IncI1 plasmids are noted in the literature for their possession of ESBL genes such as bla CTX-M .
14 E. coli ST354 harbouring bla CTX-M-9 group or bla CTX-M-1 group genes has been reported in different countries, indicating that E. coli ST354 may be a fit host for bla CTX-M plasmids. 15 -17 Noticeably, we found a complete transposition unit flanked by 5 bp DRs with the interrupted ISEcp1-bla CTX-M-137 -Dorf477 inserted into yagA, part of the IncI1 plasmid backbone, which suggests that bla CTX-M-137 was probably not created but transferred as a whole complete transposition unit in the IncI1 plasmid examined in E. coli YM11.
Because bla CTX-M-1 group and bla CTX-M-9 group genes have many homologous regions, it is likely that bla CTX-M genes are evolving by homologous recombination between members of different groups, especially when two or more bla CTX-M -type genes coexist in the same isolate, which was identified in this study with bla CTX-M-14 coexisting with bla CTX-M-22 , bla CTX-M-79 , bla CTX-M-28 and bla CTX-M-64 in 2, 5, 1 and 1 isolates, respectively. In addition, the upstream genetic structure of bla CTX-M-137 was identical to that in bla CTX-M-14 (JX442753) and the downstream structure was identical to that in bla CTX-M-15 (AB701567), which is consistent with our hypothesis that bla CTX-M-137 may have been formed by homologous recombination between bla CTX-M-14 and bla CTX-M-15 . 3 Thus, it is important to monitor food animals, the community and human clinics, as well as the environment, for the emergence and prevalence of such chimeric b-lactamase genes that may be disseminated through the food chain.
In conclusion, we identified a novel CTX-M chimera, CTX-M-137, with a CTX-M-14-like N-terminus and a CTX-M-15-like C-terminus. Our findings highlight the ongoing and complex evolution of CTX-M-type b-lactamases.
